2 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
Follow UB-421: new trials by email Literature Review of UB-421 trials Research Report on UB-421
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection UB-421 - Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-10 | 2025-07-11 | |
| the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients UB-421, Antiretroviral Therapy (ART) - HIV-1 Infection | Phase 2 | Withdrawn | United BioPharma | 2020-04-01 | 2020-02-21 |
National Institute of Allergy and Infectious Diseases (NIAID) (1) · United BioPharma (1)
United States (1)